Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGON CG Oncology	$25.55 -2.8%	$24.87	$14.80 ▼ $40.47	$1.95B	0.86	837,471 shs	987,475 shs
KYMR Kymera Therapeutics	$45.87 -1.2%	$35.05	$19.45 ▼ $53.27	$2.99B	2.07	613,377 shs	947,524 shs
MTSR Metsera	$29.60 +6.8%	$25.70	$12.30 ▼ $37.99	$3.11B	N/A	930,976 shs	2.03 million shs
VALN Valneva	$5.66 -1.1%	$6.39	$3.62 ▼ $8.66	$478.23M	1.81	42,727 shs	11,596 shs

20 High-Yield Dividend Stocks that Could Ruin Your Retirement

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGON CG Oncology	-2.78%	-1.20%	-2.56%	-5.55%	-24.61%
KYMR Kymera Therapeutics	-1.23%	-2.32%	+52.24%	+40.96%	+47.02%
MTSR Metsera	+6.82%	+0.75%	+3.21%	+5.64%	+2,959,999,900.00%
VALN Valneva	-1.12%	-5.89%	-11.97%	-21.12%	-20.34%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CGON CG Oncology	2.2235 of 5 stars	4.5	1.0	0.0	0.0	1.9	0.8	0.0
KYMR Kymera Therapeutics	3.4318 of 5 stars	4.5	3.0	0.0	0.0	3.6	1.7	0.0
MTSR Metsera	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VALN Valneva	2.8433 of 5 stars	3.5	5.0	0.0	0.0	3.1	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGON CG Oncology	3.00	Buy	$58.67	129.62% Upside
KYMR Kymera Therapeutics	3.00	Buy	$59.82	30.42% Upside
MTSR Metsera	3.00	Buy	$55.00	85.81% Upside
VALN Valneva	3.00	Buy	$15.50	174.05% Upside

Current Analyst Ratings Breakdown

Latest VALN, KYMR, CGON, and MTSR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/20/2025	MTSR Metsera	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$65.00
6/17/2025	CGON CG Oncology	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$52.00 ➝ $56.00
6/10/2025	MTSR Metsera	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$56.00 ➝ $62.00
6/3/2025	KYMR Kymera Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00
6/3/2025	KYMR Kymera Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$57.00 ➝ $64.00
6/3/2025	KYMR Kymera Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$38.00 ➝ $60.00
6/3/2025	KYMR Kymera Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$49.00 ➝ $79.00
6/2/2025	KYMR Kymera Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$51.00
5/20/2025	KYMR Kymera Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$55.00
5/19/2025	CGON CG Oncology	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$55.00 ➝ $52.00
5/13/2025	KYMR Kymera Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$72.00 ➝ $70.00

(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGON CG Oncology	$1.14M	1,708.26	N/A	N/A	$9.63 per share	2.65
KYMR Kymera Therapeutics	$47.07M	63.46	N/A	N/A	$12.90 per share	3.56
MTSR Metsera	N/A	N/A	N/A	N/A	($2.46) per share	N/A
VALN Valneva	$183.52M	2.62	$0.10 per share	57.52	$2.41 per share	2.35

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGON CG Oncology	-$88.04M	-$1.51	N/A	N/A	N/A	-15,945.17%	-16.71%	-16.24%	8/14/2025 (Estimated)
KYMR Kymera Therapeutics	-$223.86M	-$3.10	N/A	N/A	N/A	-409.07%	-30.11%	-25.65%	8/6/2025 (Estimated)
MTSR Metsera	-$209.13M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
VALN Valneva	-$13.25M	-$1.19	N/A	N/A	N/A	-43.08%	-43.05%	-16.23%	8/12/2025 (Estimated)

Latest VALN, KYMR, CGON, and MTSR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	CGON CG Oncology	-$0.36	-$0.45	-$0.09	-$0.45	$0.53 million	$0.05 million
5/12/2025	Q1 2025	MTSR Metsera	N/A	-$1.03	N/A	-$1.03	N/A	N/A
5/9/2025	Q1 2025	KYMR Kymera Therapeutics	-$0.92	-$0.82	+$0.10	-$0.82	$11.38 million	$22.10 million
5/7/2025	Q1 2025	VALN Valneva	-$0.40	-$0.13	+$0.27	-$0.13	$41.80 million	$51.79 million
3/26/2025	N/A	MTSR Metsera	N/A	-$3.52	N/A	-$3.52	N/A	N/A
3/25/2025	Q4 2024	CGON CG Oncology	-$0.37	-$0.48	-$0.11	-$0.48	$0.11 million	$0.46 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGON CG Oncology	N/A	N/A	N/A	N/A	N/A
KYMR Kymera Therapeutics	N/A	N/A	N/A	N/A	N/A
MTSR Metsera	N/A	N/A	N/A	N/A	N/A
VALN Valneva	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGON CG Oncology	N/A	30.97	30.97
KYMR Kymera Therapeutics	N/A	8.49	8.49
MTSR Metsera	N/A	6.55	6.55
VALN Valneva	0.92	2.70	2.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGON CG Oncology	26.56%
KYMR Kymera Therapeutics	N/A
MTSR Metsera	N/A
VALN Valneva	11.39%

Insider Ownership

Company	Insider Ownership
CGON CG Oncology	7.40%
KYMR Kymera Therapeutics	16.01%
MTSR Metsera	N/A
VALN Valneva	14.91%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGON CG Oncology	61	76.22 million	70.58 million	Optionable
KYMR Kymera Therapeutics	170	65.12 million	54.69 million	Optionable
MTSR Metsera	81	105.06 million	N/A	N/A
VALN Valneva	700	85.09 million	72.41 million	Not Optionable

VALN, KYMR, CGON, and MTSR Headlines

Recent News About These Companies

Valneva (NASDAQ:VALN) Shares Gap Down - Should You Sell?

June 17, 2025 | marketbeat.com

Valneva SE (NASDAQ:VALN) Sees Large Drop in Short Interest

June 14, 2025 | marketbeat.com

Valneva (NASDAQ:VALN) Stock Price Down 4% - Here's What Happened

June 12, 2025 | marketbeat.com

Chikungunya vaccine (IXCHIQ) temporarily paused in people aged 65 and over as precautionary measure

June 10, 2025 | indiaeducationdiary.in

UK's MHRA suspends Valneva's chikungunya vaccine for elderly

June 10, 2025 | reuters.com

Valneva’s Single-Shot Chikungunya Vaccine Demonstrates Durable Immune Response in Children

June 10, 2025 | pharmexec.com

UK restricts use of Valneva chikungunya vaccine for safety review

June 10, 2025 | yahoo.com

UK's MHRA suspends Valneva's chikungunya vaccine for elderly (June 9)

June 10, 2025 | msn.com

Valneva reports data from Phase II chikungunya vaccine trial in children

June 6, 2025 | finance.yahoo.com

Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ®

June 5, 2025 | globenewswire.com

Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update

June 4, 2025 | globenewswire.com

Valneva (NASDAQ:VALN) Shares Gap Down - Time to Sell?

June 3, 2025 | marketbeat.com

Valneva SE (NASDAQ:VALN) Sees Large Decrease in Short Interest

June 2, 2025 | marketbeat.com

Valneva to Participate at U.S. and European Investor Conferences in June

May 26, 2025 | globenewswire.com

US CDC accepts recommendations for chikungunya vaccines

May 21, 2025 | msn.com

London man among thousands who've rolled up their sleeves to trial Lyme disease vaccine

May 19, 2025 | cbc.ca

US Advises Older Travelers to Avoid Chikungunya Vaccine

May 16, 2025 | infectiousdiseaseadvisor.com

FDA, CDC Recommend Pause on Valneva's Chikungunya Vaccine for Seniors

May 15, 2025 | pharmexec.com

FDA, CDC recommend pause in Valneva chikungunya vaccine for older adults

May 14, 2025 | cidrap.umn.edu

U.S. Advises Older Travelers to Avoid Chikungunya Vaccine

May 13, 2025 | usnews.com

FDA warns seniors to avoid this vaccine after deadly complications

May 13, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
Analysts Think These Stocks Could More Than Double in Value
By Nathan Reiff | May 23, 2025
View Analysts Think These Stocks Could More Than Double in Value
Intel’s Turnaround May Be the Best Bet No One’s Watching
By Jeffrey Neal Johnson | May 30, 2025
View Intel’s Turnaround May Be the Best Bet No One’s Watching
Analysts Can't Get Enough of These Little-Known Biopharma Stocks
By Nathan Reiff | June 12, 2025
View Analysts Can't Get Enough of These Little-Known Biopharma Stocks

VALN, KYMR, CGON, and MTSR Company Descriptions

CG Oncology NASDAQ:CGON

$25.55 -0.73 (-2.78%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$25.54 -0.02 (-0.06%)

As of 06/20/2025 05:01 PM Eastern

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Kymera Therapeutics NASDAQ:KYMR

$45.87 -0.57 (-1.23%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$45.19 -0.68 (-1.48%)

As of 06/20/2025 07:08 PM Eastern

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Metsera NASDAQ:MTSR

$29.60 +1.89 (+6.82%)

As of 06/20/2025 04:00 PM Eastern

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.

Valneva NASDAQ:VALN

$5.66 -0.06 (-1.12%)

Closing price 06/20/2025 03:58 PM Eastern

Extended Trading

$5.66 0.00 (0.00%)

As of 06/20/2025 04:01 PM Eastern

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time